RecruitingEndometriosisAdenomyosisInfertility, Female
Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis
Eligible age
18–36 yrs
Accepts
Women
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Women suffering from endometriosis and/or adenomyosis may also suffer from infertility. GnRH agonist injection could improve implantation and therefore increase the pregnancy rate in these patients. This study was designed to evaluate effects of the additional of GnRH agonist (single or 2 doses) to the routine oestrogens and progestins use as support before Frozen Embryon Transfer as compared to oestrogens and progestins only.
Sponsor: Hopital Foch
You may qualify if…
- ✓ Women aged 18 to 36 years (women ≥18 years to \<36 years) with endometriosis and / or adenomyosis
- ✓ Having benefited from In vitro fertilisation /intracytoplasmic micro-injection with freeze all and for whom the frozen embryon transfer of a blastocyst is planned
- ✓ A normal uterine cavity
- ✓ An MRI showing endometriosis and / or adenomyosis during the inclusion visit
- ✓ Having signed a consent form
- ✓ Being affiliated to a Health Insurance Plan.
You may not qualify if…
- ✕ Patient aged \<18 years and ≥ 36 years
- ✕ BMI\> 35
- ✕ History of implantation failures (≥ 2)
- ✕ Endometrial alterations: synechiae, polyps, myomas, hyperplasia, hematometra
- ✕ known hydrosalpinx uni or bilateral
- ✕ MRI showing no endometriosis or adenomyosis
- ✕ Hypersensitivity to GnRH, GnRH analogues, or any of the excipients of Decapeptyl 3 mg
- ✕ Known hypersensitivity to estradiol
Source: ClinicalTrials.gov · NCT04356664 · last updated 2026-01-16